A Pilot Phase II Open-Label Single-Center Study of Sodium-Glucose Cotransporter-2 Inhibitor Empagliflozin in Major Depressive Disorder
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Major Depressive Disorder
-
Age: Between 18 Year(s) - 65 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provide written informed consent, as approved by the NYU Institutional Research Ethic Board (IRB).
- Patients ages 18-65.
- Current/acute MDD diagnosis, per MINI psychiatric interview.
- At least moderate severity of depression (Montgomery-Asberg Depression Rating Scale (MADRS) score of =20 at initial screen).
You may not be eligible for this study if the following are true:
-
- An individual who meets any of the following criteria will be excluded from participation in this study:
- DSM-5 diagnosis of Bipolar disorders, Cyclothymia, Schizoaffective disorder, Schizophrenia; any psychotic disorder or affective psychosis.
- Individuals who have had more than two failures of adequate anti-depressant trials in the current MDD episode.
- Individuals on on psychotropic medications other than SSRIs, NDRIs, SNRIs, or mirtazapine (occasional use of sleep agents, equivalent to lorazepam 1 mg or zolpidem 10 mg, will be allowed).
- Individuals who have previously been on SGLT2 inhibitors.
- A significant history of non-adherence to treatments.
- History of neurologic/seizure disorder.
- History of dementia/cognitive dysfunction.
- A primary diagnosis of a personality disorder, in the opinion of the screening clinician.
- DSM-5 substance use disorder (drug/alcohol) active within the past 12 months, or positive urine toxicology at screening.
- History of diabetic ketoacidosis.
- History of recurrent genital mycotic infection.
- GFR <45.
- HgA1c >8.0%.
- History of an allergic reaction to an SGLT2 inhibitor.
- Pregnancy or lactation (women of reproductive age, ie <50 years old, should be on licensed hormonal or barrier method contraception).
- Any known pancreatic disease resulting in insulin deficiency.
- History of liver or kidney disese.
- Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.